ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.040
+0.075 (7.76%)
At close: Aug 25, 2026, 4:00 PM EDT
1.032
-0.008 (-0.79%)
After-hours: Aug 25, 2026, 7:30 PM EDT
ADC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 79.58 | 81.36 | 70.84 | 69.56 | 209.91 | 33.92 | |
Revenue Growth | 3.03% | 14.85% | 1.84% | -66.86% | 518.89% | - |
Cost of Revenue | 88.81 | 107.52 | 114.06 | 129.66 | 189.76 | 159.4 |
Gross Profit | -9.23 | -26.16 | -43.23 | -60.1 | 20.15 | -125.48 |
Selling, General & Admin | 84.83 | 79.93 | 85.91 | 105.89 | 143.49 | 136.24 |
Operating Expenses | 84.83 | 79.93 | 85.91 | 105.89 | 143.49 | 136.24 |
Operating Income | -94.06 | -106.1 | -129.14 | -165.99 | -123.34 | -261.72 |
Interest Expense | -52.26 | -51.63 | -50.21 | -46.33 | -36.73 | -18.34 |
Interest & Investment Income | 8.64 | 8.81 | 12.27 | 10.54 | 2.57 | 0.07 |
Earnings From Equity Investments | - | - | -1.54 | -5.53 | -10.08 | -6.67 |
Currency Exchange Gain (Loss) | 0.48 | -0.67 | -0.08 | -0.05 | -0.11 | 0.05 |
Other Non Operating Income (Expenses) | 45.38 | 23.38 | 12.54 | 6.4 | 52.91 | 35.11 |
EBT Excluding Unusual Items | -91.83 | -126.2 | -156.16 | -200.95 | -114.79 | -251.51 |
Merger & Restructuring Charges | -9.12 | -13.12 | - | - | - | - |
Asset Writedown | 4.13 | -2.28 | -1.52 | - | - | - |
Other Unusual Items | -0.5 | - | - | - | -42.11 | - |
Pretax Income | -97.31 | -141.61 | -157.68 | -200.95 | -156.9 | -251.51 |
Income Tax Expense | -0.4 | 1.02 | 0.17 | 39.11 | 0.23 | -21.48 |
Net Income | -96.91 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 |
Net Income to Common | -96.91 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 149 | 127 | 97 | 82 | 78 | 77 |
Shares Outstanding (Diluted) | 149 | 127 | 97 | 82 | 78 | 77 |
Shares Change | 38.27% | 30.78% | 18.91% | 4.55% | 1.83% | 17.33% |
EPS (Basic) | -0.65 | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 |
EPS (Diluted) | -0.65 | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -102.3 | -141.44 | -124.7 | -121.9 | -139 | -236.81 |
Free Cash Flow Per Share | -0.69 | -1.11 | -1.28 | -1.49 | -1.78 | -3.09 |
Gross Margin | -11.59% | -32.16% | -61.02% | -86.40% | 9.60% | - |
Operating Margin | -118.19% | -130.41% | -182.30% | -238.63% | -58.76% | -771.65% |
Profit Margin | -121.77% | -175.31% | -222.83% | -345.11% | -74.86% | -678.20% |
Free Cash Flow Margin | -128.55% | -173.85% | -176.04% | -175.25% | -66.22% | -698.20% |
EBITDA | -93.71 | -105.39 | -127.8 | -164.8 | -122.28 | -260.75 |
EBITDA Margin | -117.75% | -129.54% | -180.42% | -236.92% | -58.26% | - |
D&A For EBITDA | 0.35 | 0.71 | 1.33 | 1.19 | 1.06 | 0.97 |
EBIT | -94.06 | -106.1 | -129.14 | -165.99 | -123.34 | -261.72 |
EBIT Margin | -118.19% | -130.41% | -182.30% | -238.63% | -58.76% | - |
Revenue as Reported | 79.58 | 81.36 | 70.84 | 69.56 | 209.91 | 33.92 |